Fact checked by Nick Blackmer For every health concern, someone on social media is touting a quick-fix solution—often in the ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Commenting on the commission, Dr Kath McCullough, special adviser on obesity at the Royal College of Physicians, said: “For too long, we’ve relied on BMI as a simple measure of obesity, which has ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that from 2021 to 2023, those rates dropped from 41.9% to 40.3%.

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Shares of Eli Lilly and Co. fell more than 7% in midday trading Tuesday after the Indianapolis company announced its fourth ...